Read by QxMD icon Read

Ocular brachytherapy

S Ajamil Rodanés, C García-Álvarez, M A Saornil Alvarez, F López-Lara, J M Frutos Baraja, M Quiñones
CLINICAL CASE: A 35-year-old male with unilateral ocular hypertension in the right eye (RE). Anterior segment examination of the RE showed a melanotic lesion. Intraocular pressure (IOP) was 40mmHg in RE. Gonioscopy revealed extension into the anterior chamber angle. Excisional biopsy was performed and consistent with iris melanoma and secondary melanomalytic glaucoma. Brachytherapy was performed as adjuvant therapy. DISCUSSION: In patients presenting with unilateral glaucoma and increased pigmentation in the trabecular meshwork, it is crucial to perform imaging studies...
October 13, 2016: Archivos de la Sociedad Española de Oftalmología
C A Berriochoa, J H Suh, D A Wilkinson, A Singh
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Aaron Nagiel, Daniel B Rootman, Tara A McCannel
BACKGROUND: To illustrate the evolution of paraneoplastic vitelliform maculopathy over one year using optical coherence tomography. METHODS: Observational case report. RESULTS: A 65-year-old man with a history of ocular melanocytosis and choroidal melanoma of the left eye treated with plaque brachytherapy 3 years prior returned for his yearly follow-up visit. The visual acuity in the right eye was 20/20. Subtle thickening of the interdigitation zone layer was noted on optical coherence tomography...
August 16, 2016: Retinal Cases & Brief Reports
Laoues Mostafa, Khelifi Rachid, Sidi Moussa Ahmed
Eye applicators with 90Sr/90Y and 106Ru/106Rh beta-ray sources are generally used in brachytherapy for the treatment of eye diseases as uveal melanoma. Whenever, radiation is used in treatment, dosimetry is essential. However, knowledge of the exact dose distribution is a critical decision-making to the outcome of the treatment. The Monte Carlo technique provides a powerful tool for calculation of the dose and dose distributions which helps to predict and determine the doses from different shapes of various types of eye applicators more accurately...
August 2016: Physica Medica: PM
Hali Morrison, Geetha Menon, Matthew P Larocque, Hans-Sonke Jans, Ezekiel Weis, Ron S Sloboda
PURPOSE: To estimate the total dosimetric uncertainty at the tumor apex for ocular brachytherapy treatments delivered using 16 mm Collaborative Ocular Melanoma Study (COMS) and Super9 plaques loaded with (125)I seeds in order to determine the size of the apex margin that would be required to ensure adequate dosimetric coverage of the tumor. METHODS: The total dosimetric uncertainty was assessed for three reference tumor heights: 3, 5, and 10 mm, using the Guide to the expression of Uncertainty in Measurement/National Institute of Standards and Technology approach...
August 2016: Medical Physics
Vikas Mittal, Purvasha Narang, Vikas Menon, Ruchi Mittal, Santosh Honavar
PURPOSE: To describe the utility of simple limbal epithelial transplantation (SLET) along with tumor excision in the management of extensive ocular surface squamous neoplasia (OSSN) to avoid limbal stem cell deficiency (LSCD). METHODS: This case report describes the management of a 75-year-old man clinically diagnosed with OSSN involving more than 3 quadrants of limbus. The excisional biopsy of tumor along with 4-mm healthy margin led to a complete loss of the limbus, which was restored by limbal epithelial cell transplantation using the SLET technique in the same setting...
July 20, 2016: Cornea
T Jarema, D Cutajar, M Weaver, M Petasecca, M Lerch, A Kejda, A Rosenfeld
Eye plaque brachytherapy has been developed and refined for the last 80 years, demonstrating effective results in the treatment of ocular malignancies. Current dosimetry techniques for eye plaque brachytherapy (such as TLD- and film-based techniques) are time consuming and cannot be used prior to treatment in a sterile environment. The measurement of the expected dose distribution within the eye, prior to insertion within the clinical setting, would be advantageous, as any errors in source loading will lead to an erroneous dose distribution and inferior treatment outcomes...
September 2016: Australasian Physical & Engineering Sciences in Medicine
Dominic Béliveau-Nadeau, Sonia Callejo, David Roberge
Radiotherapy has a long history in the organ-sparing management of choroidal melanoma. Joining plaque radiotherapy and proton irradiation, stereotactic robotic photon irradiation is a new tool in the radiation oncologist's armamentarium for ocular tumors. The non-coplanar fields with steep dose gradients are well suited to spare uninvolved retina, anterior chamber, and the optic nerve. In our practice, it is the preferred treatment for melanomas that are non-amenable to standard plaque brachytherapy. Since late 2010, we have treated more than 40 patients with our robotic linear accelerator...
2016: Curēus
Pia R Mendoza, Hans E Grossniklaus
BACKGROUND: Retinoblastoma is the most common primary intraocular malignancy in children. The management of retinoblastoma is complex and depends on several factors. METHODS: This review provides an update on current and emerging therapeutic options for retinoblastoma. The medical literature was searched for articles relevant to the management of retinoblastoma. The results of prospective and retrospective studies on chemotherapy and focal therapy for retinoblastoma are summarized...
April 2016: Cancer Control: Journal of the Moffitt Cancer Center
Somayeh Asadi, Mehdi Vaez-Zadeh, Mohammad Vahidian, Mahdieh Marghchouei, S Farhad Masoudi
The aim of the present Monte Carlo study is to evaluate the variation of energy deposition in healthy tissues in the human eye which is irradiated by brachytherapy sources in comparison with the resultant dose increase in the gold nanoparticle (GNP)-loaded choroidal melanoma. The effects of these nanoparticles on normal tissues are compared between 103Pd and 125I as two ophthalmic brachytherapy sources. Dose distribution in the tumor and healthy tissues has been taken into account for both brachytherapy sources...
2016: Journal of Applied Clinical Medical Physics
Hassan A Aziz, Nakul Singh, James Bena, Allan Wilkinson, Arun D Singh
IMPORTANCE: Vision loss following episcleral brachytherapy for uveal melanoma is difficult to predict for individual patients. OBJECTIVE: To generate a risk calculator for vision loss following episcleral brachytherapy for uveal melanoma. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of data was conducted at a multispecialty tertiary care center in Cleveland, Ohio. All patients with primary ciliary body or choroidal melanoma treated with iodine 125 or ruthenium 106 episcleral brachytherapy between January 1, 2004, and December 30, 2013, were included...
June 1, 2016: JAMA Ophthalmology
Timothy L Jackson, Riti Desai, Andrew Simpson, James E Neffendorf, Robert Petrarca, Kelly Smith, Janet Wittes, Cornelius Lewis, Luke Membrey, Richard Haynes, Mark Costen, David H W Steel, Alyson Muldrew, Usha Chakravarthy
PURPOSE: To assess the safety and efficacy of epimacular brachytherapy (EMB) for patients with chronic, active, neovascular age-related macular degeneration (AMD). DESIGN: Phase 3 randomized controlled trial. PARTICIPANTS: Patients (n = 363) with neovascular AMD already receiving intravitreal ranibizumab injections. INTERVENTION: Either pars plana vitrectomy with 24-gray EMB and ongoing pro re nata (PRN) ranibizumab (n = 224) or ongoing PRN ranibizumab monotherapy (n = 119)...
June 2016: Ophthalmology
J M Caminal, N Padrón-Pérez, L Arias, C Masuet-Aumatell, C Gutiérrez, J M Piulats, J Pera, J Català, M J Rubio, J Arruga
AimsThe aim of this study was to compare transscleral resection technique performed without hypotensive anaesthesia (TSRWH) with iodine-125 brachytherapy (IBT) in the treatment of choroidal melanoma.Patients and methodsThis was a retrospective surgical cohort study. Nineteen eyes treated with TSRWH were matched with 53 eyes treated with IBT according to: tumour size, distance to fovea, distance to optic nerve, and follow-up time. Best-corrected visual acuity (BCVA), local recurrence, secondary enucleation, metastasis, overall and specific survival, and complications were evaluated...
June 2016: Eye
Hiren Mandaliya, Nandini Singh, Sanila George, Mathew George
Metastatic choroid melanoma is a highly malignant disease with a limited life expectancy. The liver is the most common site for metastasis of uveal melanoma followed by lung, bone, skin, and subcutaneous tissue. Metastasis from choroidal melanoma usually occurs within the first five years of treatment for primary tumours. Metastatic choroid melanoma to the spine/vertebrae is extremely rare. We report the first case of spinal metastasis from choroid melanoma in a 61-year-old man who had been treated for primary ocular melanoma three years earlier with radioactive plaque brachytherapy...
2016: Case Reports in Ophthalmological Medicine
V Verma, M P Mehta
AIMS: Although clinical experience with proton beam radiotherapy (PBT) for most tumours is limited, there is relatively longstanding experience for uveal melanomas. Because of potential to reduce ocular toxicities, PBT is an attractive option for these tumours. However, summative data remain scarce. We systematically reviewed clinical outcomes of uveal melanoma patients treated with PBT, to comprehensively assess outcomes such as tumour control, survival, enucleation rates, toxicity and visual acuity preservation...
August 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
Yrbani Lantigua-Dorville, Maria Antonia Saornil, Ciro García-Alvarez, Elena García-Lagarto
A 68-year-old man diagnosed with choroidal melanoma (CM) in the right eye underwent treatment with episcleral brachytherapy (I125) and transpupillary thermotherapy. Ultrasound, computed tomography, and magnetic resonance imaging were performed and revealed ocular recurrence of CM. Treatment with extended enucleation was performed. Macroscopic and microscopic examinations revealed extraocular extension and malignant cells, respectively. Immunohistochemistry demonstrated tumoral Melan-A and HMB-45 expression...
February 2016: Arquivos Brasileiros de Oftalmologia
Joanna Kowal, Anna Strzałka, Anna Markiewicz, Bożena Romanowska-Dixon, Anna Bogdali
Uveal melanoma is the most common primary intraocular neoplasm in adults. Its bilateral localization is extremely rare. The aim of the paper is analysis of the cases of bilateral uveal melanoma. Five bilateral uveal melanoma patients were diagnosed in the Department of Ophtalmology and Ocular Oncology beetwen 1980 and 2014. Both eyes of four patients were threated with brachytherapy. Final enulcleation of the one eye was performed in three patients. It was the primary treatment in one patient. The presence of uveal melanoma was confirmed by pathological examination in all cases after surgical removal of eyeball and in one after local resection of iris tumor...
2015: Klinika Oczna
Sara Ferenc, Piotr Rzymski, Janusz Skowronek, Jacek Karczewski
PURPOSE: Brachytherapy (BT) plays an important role in cancer treatment. Like any other medical therapy it may, however, induce side effects whose recognition can affect the patient's quality of life. Therefore, the present study evaluated the frequency and severity of physical and psychosocial adverse effects of BT. MATERIAL AND METHODS: Patients (n = 70) undergoing high-dose-rate (HDR) BT or low-dose-rate (LDR) of head and neck, breast, and prostate cancers were interviewed face-to-face at the end of their course of treatment...
October 2015: Journal of Contemporary Brachytherapy
Siddhartha Laskar, Lavanya Gurram, Sarbani Ghosh Laskar, Suresh Chaudhari, Nehal Khanna, Rituraj Upreti
PURPOSE: The incidence of conjunctival malignancies is less than 1%. Though surgical excision remains the mainstay of treatment, the incidence of positive surgical margins and local recurrence rates are high, which is approximately up to 33% in negative margins and 56% in positive margins. Radiotherapy reduces the risk of recurrence in these cases. Brachytherapy using β emitters such as strontium-90 ((90)Sr) is an ideal treatment technique for these tumors with the advantage of treating only a few millimeters of tissue while sparing the underlying normal eye...
October 2015: Journal of Contemporary Brachytherapy
C Ellis Wisely, Mersiha Hadziahmetovic, Rachel E Reem, Erinn M Hade, Subir Nag, Frederick H Davidorf, Douglas Martin, Colleen M Cebulla
PURPOSE: To report our experience in long-term follow-up of ocular melanoma patients treated with custom OSU-Nag eye plaques using (125)I sources. METHODS: A retrospective chart review was conducted for 113 consecutive ocular melanoma patients with follow-up visual acuity data who were treated with OSU-Nag plaque episcleral brachytherapy at The Ohio State University Medical Center from 1994 to 2009. Visual acuity, complication data, and recurrence rates were recorded up to 120 months after brachytherapy...
January 2016: Brachytherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"